相关临床试验
18
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2003
进行中（未招募）
4
22.2%
已完成
6
33.3%
尚未招募
1
5.6%
招募中
6
33.3%
Unknown
1
5.6%
暂无批准数据
- The Drugs for Neglected Diseases initiative (DNDi) and Serum Institute of India (SII) have signed a licensing agreement to advance a monoclonal antibody dengue treatment into Phase III trials. - The 1,000-participant study is expected to begin in Q1 2027 across Malaysia, Thailand, and Brazil, with SII supplying the investigational drug. - The antibody, formerly known as VIS513, targets all four dengue virus serotypes and has shown promising safety and efficacy in earlier trials. - The trial is funded by the European Commission's DG HERA and the French Development Agency, with DG HERA committing €20 million to advance two dengue medicines.
- Product development partnerships have delivered more than 79 novel health tools to 2.4 billion people over nearly 30 years, prioritizing public health over market returns. - PDPs address diseases neglected by traditional pharmaceutical development, including malaria, sleeping sickness, neonatal infections, and drug-resistant bacterial infections. - Landmark PDP achievements include acoziborole for sleeping sickness, Coartem Baby for infant malaria, and zoliflodacin for drug-resistant gonorrhea. - As global health reform advances, experts argue that innovation mechanisms like PDPs must remain central to a country-led system that serves underserved populations.
- AN2 Therapeutics and DNDi announced a collaboration to advance clinical development of AN2-502998, an oral drug candidate with curative potential for chronic Chagas disease affecting 6-7 million people worldwide. - The boron-based benzoxaborole compound targets CPSF3 in T. cruzi parasites, utilizing the same mechanism as acoziborole which achieved ~95% cure rates in African sleeping sickness trials. - Phase 1 first-in-human studies are underway with completion expected in the second half of 2025, followed by Phase 2 proof-of-concept trials planned for 2026. - DNDi will provide extensive clinical trial networks across Latin America and Spain, leveraging their established Chagas Clinical Research Platform to accelerate global access to this potential breakthrough therapy.
- Dr. James Orbinski, who received the 1999 Nobel Peace Prize on behalf of Médecins Sans Frontières, has joined Fifty 1 Labs as Senior Scientist to advance AI-driven drug repurposing initiatives. - The Nevada-based biotech company unveiled a strategic plan targeting the $320.6 billion functional medicine market through its AI platform that integrates clinical trial data and patent analytics. - Company leadership invested $350,000 of personal capital and deferred salaries until reaching a $50 million valuation, with plans for OTCQB uplisting by Q1 2026. - Fifty1 AI Labs LLC, the company's subsidiary, will receive $1 million in R&D funding to develop AI-driven drug repurposing technology aimed at delivering first discovery by May 2026.
- Serum Institute of India and DNDi have signed an MoU to co-develop a monoclonal antibody treatment for dengue that targets all four virus serotypes, focusing on affordability for low- and middle-income countries. - The collaboration will advance the drug candidate through Phase III clinical trials in India, Brazil, and other dengue-endemic countries, with SII having already completed pre-clinical and Phase I/II trials demonstrating safety and efficacy. - Dengue affects 3.9 billion people globally with cases more than doubling since 2021, yet no specific treatment currently exists for the disease. - The partnership leverages SII's manufacturing capabilities and DNDi's clinical trial leadership to address the urgent need for dengue therapeutics in vulnerable populations worldwide.
- Fexinidazole Winthrop, the first all-oral treatment for Trypanosoma brucei rhodesiense sleeping sickness, is now available free of charge in Ethiopia, Malawi, and Zimbabwe. - The breakthrough treatment replaces toxic intravenous drugs requiring hospitalization with a simple oral therapy that can be taken at home with minimal observation. - Clinical trials led by DNDi demonstrated the treatment's superiority over existing drugs, leading to European Medicines Agency approval in December 2023 and WHO guideline inclusion in June 2024. - The drug is approved for patients aged six years and older weighing at least 20 kg, addressing a disease that is almost always fatal if untreated.
- A groundbreaking clinical trial for visceral leishmaniasis is underway in Liverpool, testing an oral drug (DNDi-6899) that could replace current painful injection treatments requiring hospitalization. - The collaborative effort involves NHS University Hospitals of Liverpool Group, University of Liverpool, and Drugs for Neglected Diseases initiative (DNDi) to combat a disease that affects 50,000-90,000 people annually. - Researchers aim to develop a treatment that can be easily stored, transported, and administered in low-income regions, potentially saving thousands of lives affected by this neglected tropical disease.
- A new sustained-release formulation of flucytosine for cryptococcal meningitis has entered Phase II trials in Malawi and Tanzania, simplifying dosing from four times to twice daily and improving administration options. - Cryptococcal meningitis, the second leading cause of death in patients with advanced HIV after tuberculosis, killed approximately 130,000 people in Africa in 2023 alone. - Recent HIV funding cuts threaten to reverse decades of progress, with experts warning of imminent stockouts of essential medicines like flucytosine and disruptions to advanced HIV disease services.
